CI - Cigna Corporation

NYSE - NYSE Delayed Price. Currency in USD
+0.73 (+0.46%)
At close: 4:00PM EDT

159.84 -0.03 (-0.02%)
After hours: 4:19PM EDT

Stock chart is not supported by your current browser
Previous Close159.11
Bid155.37 x 1000
Ask160.07 x 800
Day's Range158.70 - 161.07
52 Week Range141.95 - 226.61
Avg. Volume2,596,439
Market Cap60.653B
Beta (3Y Monthly)1.01
PE Ratio (TTM)14.73
EPS (TTM)10.85
Earnings DateAug 1, 2019
Forward Dividend & Yield0.04 (0.03%)
Ex-Dividend Date2019-03-08
1y Target Est214.35
Trade prices are not sourced from all markets
  • Cigna CEO on future of the company's China operations
    CNBC Videos18 days ago

    Cigna CEO on future of the company's China operations

    David Cordani, Cigna CEO, joins CNBC's Bertha Coombs to discuss the future of the company and other topics at Cigna's Investor day.

  • Business Wireyesterday

    Cigna's U.S. Loneliness Index Provides Actionable Insights for Improving Body and Mind Health

    Results from Cigna's landmark U.S. Loneliness Index were published yesterday in the American Journal of Health Promotion, as the company continues to advocate for a deeper understanding of the connectivity between physical health and emotional well-being. Nearly 50 percent of U.S. adult respondents report sometimes or always feeling alone or left out. One in four U.S. adults rarely or never feels as though there are people who understand them.

  • Radian Group (RGA) Announces Pricing of $450M Senior Notes

    Radian Group (RGA) Announces Pricing of $450M Senior Notes

    Radian Group (RDN) raised the size of the senior notes offering to $450 million from $350 million announced earlier and priced the same at a coupon rate of 4.875% per year.

  • Aetna Uncertainty Is Keeping CVS Stock Way Undervalued

    Aetna Uncertainty Is Keeping CVS Stock Way Undervalued

    It's an odd development to say the least, but a development nonetheless. Federal judge Richard Leon is attempting to prevent the merger of drugstore chain CVS Health (NYSE:CVS) and health insurer Aetna, even though the merger has already been consummated, with Aetna's value being folded into the price of CVS stock in late November.Source: Mike Mozart via FlickrAlthough rare, companies have been forced to unwind completed mergers before. They've never been forced to do so using Tunney Act proceedings, however, and legal experts doubt Leon's efforts will gain much traction.They could prove to be a drag on the CVS story, however, which is already lugging around too much dead weight.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 Healthcare Mergers Are CommonIt's not the first melding of unlike healthcare organizations we've seen of late. Cigna (NYSE:CI) now owns Express Scripts, and HCA Healthcare (NYSE:HCA) has completed its purchase of Asheville, North Carolina's Mission Health. Even (NASDAQ:AMZN), JPMorgan Chase (NYSE: JPM) and Berkshire Hathaway (NYSE:BRK.B) are teaming up to create a new healthcare outfit intended to cost-effectively serve all three organizations' employees.The common thread among these and dozens of other similar partnerships, of course, is an effort to combat the rising costs of providing healthcare. In most instances, the pairings were allowed to take shape with little fanfare.For reasons that remain mostly unclear, however, this particular deal has prompted a judicial pushback. District Judge Richard Leon's Merger HistoryThe name Richard Leon may ring a bell with some investors. The U.S. district judge is the same that oversaw the Department of Justice's effort to quell the merger of AT&T (NYSE:T) and Time Warner.Leon was largely criticized following his ruling, not just for allowing it to take shape, but for allowing it to take shape without adding any conditions.That's not his only controversial case, however. Indeed, Leon has left a trail of controversial (and often overturned) rulings behind in his career, including politically-charged ones.And, while it would be easy to chalk the judge up as a politically-motivated hack, it would also be unfair; he's proven helpful to not just both political parties, but both philosophical schools of thought. The AT&T deal with Time Warner raises many of the same concerns being raised by the union of Aetna and CVS.The crux of the still-unanswered question is the consent decree that calls for CVS to sell its Medicare Part D business to WellCare Health Plans (NYSE:WCG), while still remaining WellCare's pharmacy benefits manager. Leon's concern "is whether or not the pharmaceuticals will be [offered to WellCare customers] at a lower price and whether they're going to be more readily accessible."Still, to kill the deal at this point would step far out of the bounds of the consent decree process as it's been established. It would also step out of the accepted bounds of Tunney Act hearings. At best, says former DOJ antitrust attorney Andrea Agathoklis Murino, Leon "can say the remedy was insufficient," forcing CVS to do more than simply shed its Medicare D arm. Bottom Line for CVS StockThe development makes for thrilling headlines, though Leon's lacking legal teeth if his intent is to undo what's already been done. All the same, the renewed court battle which could last well into the summer not only serves as a nuisance but keeps shareholders uncertain as to what the company may look like a year from now. That, in turn, is keeping the value of an already-beaten-down CVS stock suppressed.What's largely being overlooked in the legal melee, however, is that such a worst-case scenario has already been more than priced in.As of its most recent look, CVS stock is trading at a dirt cheap forward-looking P/E ratio of 7.6. Even if Aetna and CVS are forced to completely split again, which is unlikely, CVS remains one of the top remaining players in the pharmacy and PBM space, if for no other reason than attrition of its rivals. The more plausible outcome of a deeper separation of its Medicare business, ultimately, could prove to go unnoticed by investors.It's certainly a trade against the current grain but surrounded by doubts and questions, CVS stock looks like a compelling contrarian trade here for investors willing to hunker down for the long haul.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site,, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 * 7 Value Stocks That Are Flying Under the Radar * 6 Mouth-Watering Fast Food Stocks for Growth Investors Compare Brokers The post Aetna Uncertainty Is Keeping CVS Stock Way Undervalued appeared first on InvestorPlace.

  • Can CVS Stock Overcome the Latest Wrench in Its Aetna Merger?
    InvestorPlace5 days ago

    Can CVS Stock Overcome the Latest Wrench in Its Aetna Merger?

    Senior Judge Richard Leon sent shares in drug store chain CVS (NYSE:CVS) lower after saying he might try to stop its $69 billion merger with Aetna (NYSE:AET), a health insurer. CVS announced the deal in December 2017. Since then, CVS stock is down over 25%. It was due to open for trade June 12 at about $54 per share. CVS' market cap of $70 billion is now just 36% of its 2018 revenue, which was $194 billion.Source: Mike Mozart via FlickrLeon told CVS' and Aetna's lawyers to "cancel their summer vacation," arguing the Department of Justice barely considered what adding 21 million customers could do for CVS' Caremark, a Pharmacy Benefit Manager (PBM).Oral arguments will be held July 17, a ruling coming shortly after. CVS has already agreed to sell its Medicare Part D plan, the only overlap with Aetna, to Wellcare, which in turn is being bought by Centene (NYSE:CNC).InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Question of CostsCentene's involvement begs the main question raised by the merger, which is whether the deal can cut healthcare costs.Centene's market advantage is cost visibility. Its business model is to profit in Medicare and Medicaid by owning clinics and other facilities its covered patients use. It was a big winner on the Obamacare exchanges, where it could offer much lower prices than standard insurance plans.The American Hospital Association opposes the CVS-Aetna merger, while supporting mergers between hospital groups, arguing that hospitals aren't the cause of health care inflation. * 10 Stocks That Every 30-Year-Old Should Buy and Hold Forever They're right. Drugs are. Combining PBMs and insurers is how the industry is fighting drug costs.CVS plans to turn 1,500 stores into "HealthHubs," after the merger, with labs, nurses and dieticians to treat chronic conditions like diabetes, representing 75% of America's health care bill.CVS has been preparing itself for a favorable outcome since February, when it reached the agreement with the Department of Justice Judge Leon is now reviewing. The Question of CompetitionLeon's objections are centered on Caremark, but that unit's problems were behind the merger in the first place.The PBM model was upended four years ago when UnitedHealth Group (NYSE:UNH), the largest private insurer, bought Catamaran, another PBM, for its own OptumRx unit.The deal made the stand-alone PBM market untenable. Since then, Express Scripts, the largest PBM, was acquired by Cigna (NYSE:CI), an Aetna rival. That merger, and the CVS-Aetna tie-up, followed failed attempts by Aetna to merge with Humana (NYSE:HUM) and by Cigna to merger with Anthem (NASDAQ:ANTM). Having failed at horizontal mergers because of their size (despite UnitedHealth being bigger than either combination), the second-tier players moved toward vertical mergers, hoping to compete through cost control.Thus, Leon seems intent on stopping a train that has already left the station. UnitedHealth, Centene and Cigna own PBMs, and he's going to stop CVS-Aetna because CVS owns one? The Bottom Line on CVS StockNot all mergers work. CVS' own acquisition of Omnicare, a long-term care provider, caused it take a $3.9 billion write-down in the second quarter of last year, and a net loss for all of 2018. * 7 U.S. Stocks to Buy With Limited Trade War Exposure But given how far insurers have gone along the road to matching income with outgo, the Aetna merger was looking like a winner. The delays have pushed CVS shares down enough to give its 50 cent per share dividend a yield of 3.82%, even though absent of write-offs, it covers that dividend with earnings two to three times over each year.The Leon delay looks like a good opportunity for income investors to grab a bargain.Dana Blankenhorn is a financial and technology journalist. He is the author of the mystery thriller, The Reluctant Detective Finds Her Family, available at the Amazon Kindle store. Write him at or follow him on Twitter at @danablankenhorn. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 High-Quality Cheap Stocks to Buy With $10 * 7 U.S. Stocks to Buy With Limited Trade War Exposure * 6 Growth Stocks That Could Be the Next Big Thing Compare Brokers The post Can CVS Stock Overcome the Latest Wrench in Its Aetna Merger? appeared first on InvestorPlace.

  • Business Wire6 days ago

    Cigna Ranked First in the Health Care Industry for Supporting Healthy Communities and Families

    Global health service company Cigna ranked first in the health care industry and ranked second on a new list of Top 100 U.S. Companies Supporting Healthy Communities and Families. The list, compiled by JUST Capital with support from Robert Wood Johnson Foundation, recognizes leading organizations that prioritize community health through supportive and sustainable business practices to improve the lives of employees, customers and neighbors. “At Cigna, we are committed to creating a better future, together,” said David M. Cordani, president and CEO of Cigna.

  • ‘I’m simply trying not to die,’ says one advocate as senior Democrats reluctantly give ‘Medicare for All’ more attention
    MarketWatch6 days ago

    ‘I’m simply trying not to die,’ says one advocate as senior Democrats reluctantly give ‘Medicare for All’ more attention

    “Medicare for All” got a hearing Wednesday before a powerful House panel, but there continued to be signs that top Democrats aren’t embracing the issue.

  • BB&T Atlanta Open moves to larger site
    American City Business Journals7 days ago

    BB&T Atlanta Open moves to larger site

    The ninth-annual BB&T; Atlanta Open, scheduled for July 20-28, is in its first year of a new 5-year contract with Atlantic Station.

  • United Way appoints 2019 campaign chairs
    American City Business Journals7 days ago

    United Way appoints 2019 campaign chairs

    Tim Wentworth, president of Express Scripts and Cigna Services, and law firm Husch Blackwell's chairman, Greg Smith, will co-chair the 2019 fall fundraising campaign for the United Way of Greater St. Louis.

  • TheStreet.com7 days ago

    Cigna Looks Poised for a Rally to Break 6-Month Decline

    Here's what Jim Cramer had to say about Cigna Corp. during the "Mad Money" Lightning Round on Monday evening: "I want you to buy some more. In this daily bar chart of CI, below, we can see some positive developments.

  • Markit8 days ago

    See what the IHS Markit Score report has to say about Cigna Corp.

    Cigna Corp NYSE:CIView full report here! Summary * Perception of the company's creditworthiness is positive * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for CI with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CI. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding CI totaled $5.35 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator. CI credit default swap spreads are near the lowest level of the last one year and indicate improvement in the market's perception of the company's credit worthiness.Please send all inquiries related to the report to and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Is Cigna (CI) a Suitable Stock for Value Investors Now?
    Zacks11 days ago

    Is Cigna (CI) a Suitable Stock for Value Investors Now?

    Let's see if Cigna Corporation (CI) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

  • Here is What Hedge Funds Think About CIGNA Corporation (CI)
    Insider Monkey12 days ago

    Here is What Hedge Funds Think About CIGNA Corporation (CI)

    We at Insider Monkey have gone over 738 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st. In this article, we look at what those funds think of CIGNA Corporation (NYSE:CI) based on that data. […]

  • 16 international startups eye local health care partnerships at GlobalSTL innovation summit
    American City Business Journals14 days ago

    16 international startups eye local health care partnerships at GlobalSTL innovation summit

    GlobalSTL will play matchmaker on Wednesday between 16 international startups hoping to land a lucrative deal with some of St. Louis’ major players in the health care industry.

  • Business Wire14 days ago

    Cigna Foundation Supports Social Connectivity through $150,000 Grant to FiftyForward

    The Cigna Foundation announced a $150,000 grant over three years to FiftyForward in Nashville to provide day services for adults aged 50 and older who are experiencing cognitive or physical health challenges. “We share FiftyForward’s goal to help people overcome significant health challenges to live independent, engaged and healthy lives,” said Susan Stith, executive director, Cigna Foundation.

  • Morningstar14 days ago

    Ultimate Stock-Pickers' Top 10 Buys and Sells

    For the past nine years, our primary goal with Ultimate Stock-Pickers has been to uncover investment ideas our equity analysts and top investment managers find attractive, in a manner timely enough for investors to gain some value. As part of this process, we scour the quarterly (in some cases, the monthly) holdings of 26 different investment managers: 22 managers oversee mutual funds covered by Morningstar's manager research group and four Stock-Pickers run the investment portfolios of large insurance companies. In our last article, we walked through the Ultimate Stock-Pickers' purchasing activity during the first quarter of 2019.

  • Are Investors Undervaluing Cigna (CI) Right Now?
    Zacks15 days ago

    Are Investors Undervaluing Cigna (CI) Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • 3 Reasons Why Cigna (CI) Is a Great Growth Stock
    Zacks15 days ago

    3 Reasons Why Cigna (CI) Is a Great Growth Stock

    Cigna (CI) possesses solid growth attributes, which could help it handily outperform the market.

  • Cigna (CI) Down 6.5% Since Last Earnings Report: Can It Rebound?
    Zacks17 days ago

    Cigna (CI) Down 6.5% Since Last Earnings Report: Can It Rebound?

    Cigna (CI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Business Wire19 days ago

    Cigna Collaboration Helps Santa Clara County IPA (SCCIPA) Improve Quality and Lower Costs

    The latest results from a collaboration between Cigna and Santa Clara County IPA show that the program continues to drive better health care quality for nearly 18,000 Silicon Valley residents while achieving significantly better affordability.

  • Cigna exec picked as COO of growing Atlanta health IT company
    American City Business Journals20 days ago

    Cigna exec picked as COO of growing Atlanta health IT company

    BioIQ named a health care veteran as the company's new COO, with responsibilities that include delivering scalable solutions for its clients.

  • The Top Health Care Companies in the World
    Investopedia20 days ago

    The Top Health Care Companies in the World

    An introduction to health care companies that are tops in their fields. From health care provider to pharmaceuticals, these companies have the largest global presence according to market capitalization. Learn who these health care giants are and why they may be a good investment.

  • Reuters25 days ago

    For Anderson family, an early bet on SMA gene therapy

    When Malachi Anderson was diagnosed with a rare and often deadly disease called spinal muscular atrophy (SMA) as an infant nearly four years ago, his parents Tina and Torence had a decision to make. In years past, many of the babies born with the most severe form of SMA, like Malachi, died before their second birthday. By 2015, drugmakers were testing two experimental therapies in clinical trials: a one-time gene therapy treatment that is now owned by Novartis AG and Spinraza, a Biogen Inc drug which is given through spinal infusion every four months, indefinitely.